Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 25.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 16.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Unternehmen & Branche
| Name | Nuvectis Pharma, Inc. |
|---|---|
| Ticker | NVCT |
| CIK | 0001875558 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 227,8 Mio. USD |
| Beta | -0,21 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -26,442,000 | -1.32 | 31,709,000 | 18,413,000 | |
| 2025-09-30 | 10-Q | -7,462,000 | -0.44 | 35,587,000 | 24,010,000 | |
| 2025-06-30 | 10-Q | -6,334,000 | -0.30 | 27,007,000 | 16,872,000 | |
| 2025-03-31 | 10-Q | -5,332,000 | -0.27 | 30,148,000 | 20,954,000 | |
| 2024-12-31 | 10-K | -19,000,000 | -1.11 | 18,607,000 | 9,713,000 | |
| 2024-09-30 | 10-Q | -4,153,000 | -0.24 | 17,307,000 | 10,991,000 | |
| 2024-06-30 | 10-Q | -4,428,000 | -0.26 | 18,298,000 | 12,528,000 | |
| 2024-03-31 | 10-Q | -4,171,000 | -0.25 | 19,714,000 | 14,022,000 | |
| 2023-12-31 | 10-K | -22,260,000 | -1.43 | 19,185,000 | 12,201,000 | |
| 2023-09-30 | 10-Q | -5,881,000 | -0.37 | 22,262,000 | 16,686,000 | |
| 2023-06-30 | 10-Q | -5,708,000 | -0.38 | 24,941,000 | 20,332,000 | |
| 2023-03-31 | 10-Q | -4,049,000 | -0.27 | 16,208,000 | 12,274,000 | |
| 2022-12-31 | 10-K | -19,085,000 | -1.51 | 20,405,000 | 14,219,000 | |
| 2022-09-30 | 10-Q | -5,877,000 | -0.42 | 24,866,000 | 20,374,000 | |
| 2022-06-30 | 10-Q | -3,569,000 | -0.28 | 14,238,000 | 11,500,000 | |
| 2022-03-31 | 10-Q | -2,943,000 | -0.32 | 17,618,000 | 14,559,000 | |
| 2021-12-31 | 10-K | -12,890,000 | -3.02 | 6,657,000 | -11,008,000 | |
| 2021-09-30 | 10-Q | -4,668,000 | -1.04 | -8,932,000 | ||
| 2021-06-30 | 10-Q | -5,938,000 | -1.43 | -4,400,000 | ||
| 2021-03-31 | 10-Q | -23,000 | 0.01 | -33,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-05 | BENTSUR RON | Director, Officer, 10% Owner, Chairman & CEO | Open Market Purchase | 5,000 | 5.72 | 28,600.00 | +31,4% | |
| 2025-11-05 | Kaplan Matthew L. | Director | Open Market Purchase | 11,000 | 5.84 | 64,240.00 | +70,6% | |
| 2025-11-05 | Sanchez Juan | Director | Open Market Purchase | 13,000 | 5.79 | 75,270.00 | +82,7% | |
| 2025-10-27 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 72,836 | 6.28 | 457,410.08 | +502,6% | |
| 2025-10-24 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 35,034 | 6.15 | 215,459.10 | +236,7% | |
| 2025-10-23 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 46,900 | 6.06 | 284,214.00 | +312,3% | |
| 2025-06-20 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 5,603 | 7.99 | 44,767.97 | +49,2% | |
| 2025-06-18 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 28,043 | 8.05 | 225,746.15 | +248,0% | |
| 2025-06-17 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 5,399 | 8.11 | 43,785.89 | +48,1% | |
| 2025-05-12 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 21,167 | 8.11 | 171,664.37 | +188,6% | |
| 2025-05-09 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 9,817 | 8.90 | 87,411.55 | +96,0% | |
| 2025-05-09 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 5,395 | 8.98 | 48,425.52 | +53,2% | |
| 2025-05-09 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 9,850 | 8.95 | 88,127.95 | +96,8% | |
| 2025-05-08 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 50 | 8.65 | 432.50 | +0,5% | |
| 2025-05-08 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 2,400 | 8.97 | 21,528.00 | +23,7% | |
| 2025-05-08 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 100 | 8.99 | 899.00 | +1,0% | |
| 2025-05-08 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 100 | 8.71 | 871.00 | +1,0% | |
| 2025-05-08 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 2,400 | 8.65 | 20,760.00 | +22,8% | |
| 2025-05-08 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 100 | 8.65 | 865.00 | +1,0% | |
| 2025-05-07 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 9,614 | 8.64 | 83,064.96 | +91,3% | |
| 2025-05-07 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 2,703 | 8.40 | 22,705.20 | +24,9% | |
| 2025-05-06 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 10,104 | 8.64 | 87,298.56 | +95,9% | |
| 2025-05-06 | Mosseri Marlio Charles | 10% Owner | Open Market Purchase | 2,340 | 8.40 | 19,656.00 | +21,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.